| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Penicillin-binding proteins (PBPs) in bacterial cell walls. Amoxicillin inhibits the transpeptidase enzyme involved in peptidoglycan synthesis, leading to bacterial cell lysis.
|
|---|---|
| ln Vitro |
In a dose-dependent manner, amoxycillin arginine (1-100 µM; 24 hours; Lactobacillus acidophilus) decreases viable cells and increases breakdown of the cell wall [1].
In vitro, Amoxicillin arginine exhibits broad-spectrum antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria, including Streptococcus pneumoniae, Staphylococcus aureus (non-resistant strains), Escherichia coli, Haemophilus influenzae, and Neisseria gonorrhoeae. The minimum inhibitory concentrations (MICs) are comparable to those of amoxicillin free base. The arginine salt form may have enhanced solubility, leading to improved bioavailability. The compound inhibits cell wall biosynthesis in susceptible bacteria. |
| ln Vivo |
At doses of 1 mg/L or less, amoxycillin (Amoxycillin) arginine (7 mg/kg; ih; female ICR/Swiss mice) reduces the number of strains and increases rat survival rates [2]. The Chlamydia trachomatis infection in mice can be resisted by amoxycillin (Amoxycillin) arginine (1.6-9.5 mg/kg; oral; once daily for 7 or 14 days; Swiss albino mice) [3].
In vivo, Amoxicillin arginine has been shown to be effective in animal models of bacterial infection, including pneumonia, septicemia, and skin infections. The compound has good oral absorption and achieves therapeutic concentrations in plasma and tissues. It is used in pharmacokinetic and pharmacodynamic studies to evaluate its efficacy against various bacterial pathogens. The arginine salt form may offer advantages in terms of solubility and absorption compared to the free base. |
| Enzyme Assay |
The antibacterial activity of Amoxicillin arginine is assessed using the broth microdilution method according to CLSI guidelines. Bacterial cultures (e.g., S. aureus, E. coli) are grown to logarithmic phase in Mueller-Hinton broth. Serial dilutions of the compound (0.015–256 µg/mL) are added to 96-well plates, and bacteria are inoculated at a density of 5×10⁵ CFU/mL. Plates are incubated at 37°C for 16–24 hours. The minimum inhibitory concentration (MIC) is determined as the lowest concentration inhibiting visible bacterial growth.
|
| Cell Assay |
Bacterial cultures (e.g., S. aureus, E. coli) are grown to logarithmic phase and treated with Amoxicillin arginine at various concentrations (0.015–256 µg/mL) for 16–24 hours. Bacterial growth is monitored by measuring optical density at 600 nm. The MIC is determined as the lowest concentration inhibiting visible bacterial growth. Time-kill curves may be performed to assess the bactericidal activity of the compound. Cytotoxicity is assessed in mammalian cell lines (e.g., HEK293, HepG2) using MTT assay to determine CC50.
|
| Animal Protocol |
Animal/Disease Models: Female ICR/Swiss mice [2]
Doses: 7 mg/kg Route of Administration: subcutaneous injection; every 8 hrs (hrs (hours)) for 24 hrs (hrs (hours)) Experimental Results: Inhibition of bacterial counts in a dose-dependent manner. Animal/Disease Models: Female ICR/Swiss mice [2] Doses: 7 mg/kg Route of Administration: subcutaneous injection; every 8 hrs (hrs (hours)) for 4 days Experimental Results: All animals infected with microorganisms with a MIC of 1 mg/L or less All survived, with mortality ranging from 20% to 40% in animals infected with both strains with an MIC of 2 mg/L. Animal/Disease Models: Swiss albino mice [3] Doses: 1.6 and 9.5 mg/kg Route of Administration: Oral; one time/day for 7 or 14 days Experimental Results: Improved activity in mice infected with Chlamydia trachomatis. In murine infection models, mice are inoculated with a lethal dose of pathogenic bacteria (e.g., S. pneumoniae, E. coli) via intraperitoneal or intravenous injection. Amoxicillin arginine is administered orally or subcutaneously at doses of 5–50 mg/kg, starting 1–2 hours after infection, and continued for 3–5 days. Survival rates, bacterial load in target organs (e.g., blood, lungs, spleen), and pharmacokinetic-pharmacodynamic relationships are assessed. |
| References |
|
| Molecular Formula |
C22H33N7O7S
|
|---|---|
| Molecular Weight |
539.6
|
| Exact Mass |
539.216
|
| CAS # |
59261-05-1
|
| Related CAS # |
Amoxicillin sodium;34642-77-8;Amoxicillin;26787-78-0;Amoxicillin trihydrate;61336-70-7;Amoxicillin-d4;2673270-36-3;Amoxicillin trihydrate mixture with potassium clavulanate (4:1)
|
| PubChem CID |
216387
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
286
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
37
|
| Complexity |
767
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C.C(CC(C(=O)O)N)CN=C(N)N
|
| InChi Key |
GMJWAEBOPBLHBW-KZYOBBJWSA-N
|
| InChi Code |
InChI=1S/C16H19N3O5S.C6H14N4O2/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;7-4(5(11)12)2-1-3-10-6(8)9/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t9?,10-,11?,14-;4-/m00/s1
|
| Chemical Name |
(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(5S,6S)-6-[[2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
|
| Synonyms |
Amoxycillin arginine salt EINECS 261-680-4 Amoxycillin L-arginine salt
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8532 mL | 9.2661 mL | 18.5322 mL | |
| 5 mM | 0.3706 mL | 1.8532 mL | 3.7064 mL | |
| 10 mM | 0.1853 mL | 0.9266 mL | 1.8532 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.